These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10030769)

  • 21. Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
    Lori F
    AIDS; 1999 Aug; 13(12):1433-42. PubMed ID: 10465065
    [No Abstract]   [Full Text] [Related]  

  • 22. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea.
    Gortner C
    BETA; 1998 Oct; ():7. PubMed ID: 11365996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea: what it is. New Mexico AIDS InfoNet.
    Newsline People AIDS Coalit N Y; 1998 Mar; ():15. PubMed ID: 11367449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host factors and efficacy of antiretroviral treatment.
    Turriziani O; Antonelli G
    New Microbiol; 2004 Apr; 27(2 Suppl 1):63-9. PubMed ID: 15646066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy of human immunodeficiency virus (HIV) infection based on chemotherapeutic intervention with early steps of the virus replicative cycle.
    De Clercq E
    Postepy Biochem; 1995; 41(5 Suppl):338-42. PubMed ID: 8797234
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hydroxyurea and HIV infection].
    Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
    Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
    Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
    AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
    J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
    Lisziewicz J; Jessen H; Finzi D; Siliciano RF; Lori F
    Lancet; 1998 Jul; 352(9123):199-200. PubMed ID: 9683211
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
    Mansky LM; Pearl DK; Gajary LC
    J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
    Lori F; Lisziewicz J
    Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
    Gao WY; Johns DG; Chokekuchai S; Mitsuya H
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8333-7. PubMed ID: 7667290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies towards HIV-1 infection in macrophages.
    Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S
    Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea, a potential new anti-HIV agent.
    Torres G
    GMHC Treat Issues; 1995 Jan; 9(1):7-9. PubMed ID: 11367381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenothiazines in treatment of HIV infection (a review).
    Aszalos A
    Acta Microbiol Immunol Hung; 2003; 50(1):43-53. PubMed ID: 12793200
    [No Abstract]   [Full Text] [Related]  

  • 39. Sequencing antiretroviral drugs for long-lasting suppression of HIV replication.
    Gianotti N; Lazzarin A
    New Microbiol; 2005 Oct; 28(4):281-97. PubMed ID: 16386013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
    Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.